|
EP3095440A1
|
|
Antigen-specific immunotherapy using tolerizing liposomes
|
|
EP2918262A1
|
|
Induction of antigen-specific tolerance by peripheral phagocytosis
|
|
EP2813242A1
|
|
Low molecular weight immune-modulators as adjuvants for specific immunotherapy
|
|
EP2746396A1
|
|
Selective local inhibition of TNFR1-mediated functions at the site of antigen/allergen presentation
|
|
EP2674168A1
|
|
Modulation of effector T cell responses by local depletion of complement component C3
|
|
EP2674167A1
|
|
Controlled activation of complement components for use as endogenous adjuvant
|
|
EP2596802A1
|
|
Pharmaceutical composition for treatment of allergic reactions
|
|
EP2309263A1
|
|
Chimeric IgY Fc receptor constructs
|
|
EP2243791A1
|
|
Cloning and recombinant production of Vespula venom protease and methods of use thereof
|
|
EP1873165A1
|
|
Cloning of honey bee allergen C
|
|
EP1846556A1
|
|
Cloning of honey bee allergen
|
|
EP1777524A1
|
|
Chimera of human IgE receptor alpha-chain and avian constant immunoglobulin domains for the determination of serum IgE
|
|
EP1757622A1
|
|
Bivalent IgY antibody constructs for diagnostic and therapeutic applications
|
|
US7553931B2
|
|
Complement depletion using recombinant human C3-derivatives
|
